TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Inpatients required tracheal intubation under general anesthesia and a non-emergency non-cardiothoracic and non-extracranial elective surgery for an estimated duration of ≤ 3 h ;.~2. Males or females, aged ≥ 18 and ≤ 65 years old;~3. Body mass index (BMI) ≥ 19 and ≤ 30 kg/m2;~4. ASA grade I\~II;~5. Capable of understanding the procedure and method of this study, willing to sign an informed consent form and to complete this study in strict accordance with the study protocol.~Exclusion Criteria:~1. Patients were contraindicated in general anesthesia.;~2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products or a medical condition such that these agents were contraindicated~3. Patients in receipt of any investigational drug within 30 days before screening.~4. Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics within one month prior to the screening period.~5. Patients in receipt of general anesthesia surgery within two weeks prior to the screening period.~6. The patient has some history or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, liver, kidney, blood system, or metabolic system disease prior to the screening period.~7. Abnormal laboratory results consisting of any of the following: :~1) AST and ALT≥ 2×ULN； 2）TBIL≥ 1.5×ULN； 3）Hb≤ 90g/L; 4）ANC≤1.5×109/L; 5) PLT≤80×109/L； 6） serum creatinine≥ 1.5×ULN.~8. Patients with a history of drug or ethanol abuse with the past 3 months. 9. Pregnant women or female patients with a positive serum or urine human chorionic gonadotropin pregnancy test at screening or baseline or lactating female patients. . 10. 10. Patients with a positive Allen 's test who collected arterial blood for PK study.~11. Patients with respiratory management difficulties. 12. Patients with an inability to communicate well with the investigator, or deemed unsuitable according to the investigator (in each case providing a reason).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HSK3486 (Type: EXPERIMENTAL): Dose Escalation Cohort:~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg.
- Propofol (Type: ACTIVE_COMPARATOR): Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to DSM-IV-TR criteria~* Has been able to achieve outpatient status for more than 3 months in the past year~* Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)~* Resides in a stable living situation~* Willing and able to be confined to an inpatient study unit for 2 weeks or longer~Exclusion Criteria:~* History of poor or inadequate clinical response to treatment with aripiprazole~* History of treatment resistance~* Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)~* Diagnosis of current substance dependence (including alcohol)~* Pregnant, lactating, or breastfeeding~* Receipt of any antipsychotic medication by IM injection within 60 days before Screening~* Current involuntary hospitalization or incarceration~* Hospitalized for more than 30 days during the 90 days before Screening~Additional inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 9072 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (\>18 years old).~2. Breast cancer patients who will receive adjuvant weekly paclitaxel for 12 cycles.~3. ECOG performance status 0-2~4. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \<1.5 mg/dl).~Exclusion Criteria:~1. Patients who have any of the following:~   * Clinical neuropathy.~  * Diabetes mellitus.~2. Patients receiving vitamin B1, B6, B12,or other vitamin supplemental therapy.~3. Patients receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.~4. Hypersensitivity to NAC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: ACTIVE_COMPARATOR): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
- high dose N-acetyl cysteine (Type: EXPERIMENTAL): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
- low dose N-acetyl cysteine (Type: EXPERIMENTAL): they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Adults aged 40-70 years.~2. Diagnosis of type 2 diabetes within the previous 8 years using criteria of the American Diabetes Association~3. Currently treated with no hypoglycemic agents other than a stable dose (\>3 months) of metformin (≥1.0 to ≤2 grams daily).~4. HbA1C between 6 to 9% (both inclusive)~5. BMI 25 to 39.9 kg/m2 (both inclusive)~Exclusion Criteria:~1. Contraindications for moderate exercise~2. Implanted devices (e.g., pacemakers) that may interact with Tanita scale~3. Previous coronary or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or peripheral vascular disease.~4. Low hematocrit \<28 Units~5. Pre-existing liver disease and/or ALT and AST \>2.5X's UNL~6. Kidney disease (serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women,Creatinine Clearance ≤50 mL/min)~7. History of pancreatitis, or cancer (except basal cell carcinoma)~8. Statin use started (or dose change) in the last 3 months.~9. Use of oral or injectable anti-diabetic medication other than Metformin~10. Use of any form of consistent-long term steroid medication (oral, inhaled injected or nasal) within the last 3 months~11. Systolic BP\> 140 mmHg and diastolic BP\> 90 mmHg~12. Active wounds or recent surgery within 3 months.~13. Inflammatory disease, or current use of anti-inflammatory drugs~14. triglycerides \>400 mg/dL~15. untreated hyper/hypothyroidism Additionally, patients who are active smokers, patients who are pregnant, nursing women, and post menopausal women who are on hormone replacement therapy will be excluded.~Patients on low dose oral contraceptives will be allowed to participate as these formulations contain lesser amount of estrogens.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo 1 pill daily for 12 weeks
- saxagliptin (Type: ACTIVE_COMPARATOR): Saxagliptin 5mg once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe glabellar frown lines~* Female or male, 30 to 65 years of age in good general health~* Women of childbearing potential must agree to use an effective method of birth control during the course of the study~* Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response~Exclusion Criteria:~* Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and myasthenia gravis~* Muscle weakness or paralysis, particularly in the treatment area~* Active skin disease or infections or irritation at the treatment area~* Facial asymmetry, deep dermal scarring, or inability to substantially lessen the glabellar frown lines by manually spreading them apart~* Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last 3 months anywhere in the body

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dose A (Type: EXPERIMENTAL): Dose A: Botulinum Toxin Type A
- Dose B (Type: EXPERIMENTAL): Dose B: Botulinum Toxin Type A
- Dose C (Type: EXPERIMENTAL): Dose C: Botulinum Toxin Type A
- Dose D (Type: ACTIVE_COMPARATOR): Dose D: Botulinum Toxin Type A
- Dose E (Type: PLACEBO_COMPARATOR): Dose E: Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Pain Optimization After Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ages 3 to 17 years old~* Presenting for elective tonsillectomy +/- adenoidectomy~* Provide informed consent / assent (as appropriate)~Exclusion Criteria:~* History of liver or kidney disease~* Females with positive pregnancy test~* Severe sleep apnea (Sleep study with Apnea Hypopnea Index (AHI) \> 10)~* Consistent daily opioid use for chronic pain ( \>3 months)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Short acting opioids: Fentanyl, Hydromorphone (Type: ACTIVE_COMPARATOR): None
- Long Acting Opioid: Methadone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  * Previously treated disease~* Candidate for high-dose chemotherapy with melphalan and autologous stem cell transplantation~* No definite evidence of myelodysplasia on pretreatment bone marrow by morphology or by chromosome analysis (e.g., monosomy 7)~  * Chromosome abnormalities from the myeloma clone allowed~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 2.0 mg/dL~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine ≤ 2 times ULN~* LVEF ≥ 45%~* Corrected pulmonary diffusion capacity ≥ 50%~* No uncontrolled infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other active malignancy (with the exception of nonmelanoma skin cancer) that requires myelosuppressive chemotherapy or radiation therapy~* No HIV positivity~PRIOR CONCURRENT THERAPY:~* More than 3 weeks since prior myelosuppressive chemotherapy, except cyclophosphamide pulsing for stem cell collection)~* No other concurrent immunotherapy, radiotherapy, chemotherapy or antimyeloma therapy~* Concurrent chronic corticosteroids at doses of prednisone ≤ 20 mg per day (or equivalent) allowed~* Concurrent adjuvant hormonal therapy (e.g., tamoxifen citrate or leuprolide acetate) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab + Zevalin (Type: EXPERIMENTAL): Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.~Have a treatment history of an inadequate ADT response to at least 1 ADT (but not \> 3) for the current episode.~Have received a single, trial-approved, SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening.~Are 18 to 35 years old at the time of consent (inclusive, and outpatients only).~Are (and will be) working 20 hours or more per week or a student taking 6 credit hours or more during the trial period, however minor deviations from the part-time concept may be acceptable on a case-by-case basis based on approval of the medical monitor.~Have a Hamilton Depression Rating Scale (HAM-D)- 17-item Total Score ≥ 18 at screening and baseline.~Have a Sheehan Disability Scale (SDS) 3-item mean score ≥ 5 at baseline.~Main Exclusion Criteria:~Subjects with any of the following current Axis I DSM-IV-TR diagnoses: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified (NOS); eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; post-traumatic stress disorder; and attention deficit hyperactivity disorder.~Subjects with any of the following current Axis II DSM-IV-TR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Up to 3mg/day, once daily dose, tablets, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of solid tumor, including but not limited to, the following:~  * Stage II-IV germ cell malignancy~ * Small cell lung cancer~ * Recurrent breast cancer OR~* Diagnosis of lymphoma~* About to start a program of antineoplastic chemotherapy for malignant disease that will regularly induce myelosuppression with a risk of temporary severe neutropenia (i.e., neutrophil count less than 500/mm3), but does not routinely require filgrastim (G-CSF) or stem cell support~* Not previously randomized into the Significant trial for a different multicourse chemotherapy program~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Sex:~* Not specified~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Not specified~Renal:~* Creatinine normal OR~* Creatinine clearance greater than 40 mL/min~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception in addition to oral contraceptive pills~* HIV negative~* No epilepsy~* No history of adverse events resulting from fluoroquinolone therapy (e.g., allergy or tendinitis)~* No concurrent use of a sunbed or exposure to strong sunlight~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No other concurrent antibacterial therapy~* No other concurrent prophylactic antibacterial agents including cotrimoxazole prophylaxis against Pneumocystis carinii~* No iron supplements, sucralfate, or mineral antacids 2 hours before or after study medication~* Concurrent entry into other clinical trials allowed

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases~* Decision to initiate treatment with Radium-223 was made as per investigator's routine treatment practice~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Type: None): Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First episode of unprovoked and provoked proximal DVT of the lower limbs and treated for 3 month with oral anticoagulants~Exclusion Criteria:~* Active cancer,~* Limited life expectancy,~* Antiphospholipid antibody syndrome, or an other known thrombophilic status (such as antithrombin deficiency),~* Serious liver disease,~* Renal insufficiency (serum creatinine \> 2 mg/dL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy in both lower extremities~* Lower extremity pain for at least 3 months~* Stable treatment of diabetes with drugs or diet for at least 3 months~* Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of \<10%)~* Documented daily pain on at least 4 of 7 days during baseline period (pain rated at least 5 on scale of 11)~* In generally good health~* If female of childbearing potential, using acceptable method of birth control~Exclusion Criteria:~* No failed trials of tramadol HCl or tramadol HCl/acetaminophen~* No participation in more than 2 clinical trials for treatment of neuropathic pain~* No more than 2 failed trials of medications for neuropathic pain~* No use of prohibited concomitant medications~* No peripheral neuropathy caused by condition other than diabetes~* No other pain more severe than neuropathic pain~* No progressive or degenerative neurological disorder~* No painful peripheral diabetic neuropathy for \> 10 years~* No kidney or liver dysfunction~* Not pregnant or breast-feeding~* No unstable medical disease~* No clinically significant medical conditions~* No condition that might affect the way the body absorbs or processes the study drug~* No history of suicide attempt/tendencies~* No major psychiatric disorder in past 6 months~* No history of drug or alcohol abuse/dependance in the past 2 years~* No amputations~* No active infection of the lower extremity~* No active foot ulcer~* No use of an investigational drug in past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete